Systematic review of Yanshu injection plus vinorelbine and cisplatin treatment of non-small cell lung cancer

Objective To systematically evaluate the clinical efficacy and safety of vinorelbine combined with visplatin(NP regimen) and Yanshu injection cures for non-small cell lung cancer(NSCLC) in the later period. Methods With the automatic search of CNKI,VIP,CBM,Wanfang,PubMed and the Cochrane Library,we searched some related journals and magazines in the field,to collect randomized control trials(RCTs) that vonorelbine combined with cisplatin cures for NSCLC.Two researchers selected RCTs independently by the standard of exclusion,assessed the quality,extracted data,and analyzed with the aid of Revman5.0. Results Ten RCTs were adopted,including 726 terminal patients of NSCLC.It was reported that all of the researches adopted the method of randomized control,but it was not reported in detail whether allocation concealment and bi-blind were used.Meta analyses showed that Yanshu injection plus NP can improve the effect of chemotherapy(RR=1.33,95%CI=1.10-1.59,P0.01),advance the living standard of patients(RR=1.69,95%CI=1.39-2.05,P0.01),reduce the occurrence of myelosuppression(RR=0.08,95%CI=0.72-0.88,P0.01),lower the stomach intestine reaction(RR=0.75,95%CI=0.68-0.84,P0.01). Conclusion Yanshu injection plus NP can improve the efficiency in the treatment of NSCLC and the living standard of patients,reduce myelosuppression and stomach intestine reaction,etc,which are resulted from chemotherapy,and relieve the suffering of cancer.Therefore,it is easier for terminal patients of NSCLC to accept,and necessary for further research and clinical spread.However,the poor quality of research method restricted the validity of results,so more high-quality and large-sample studies are needed.